Literature DB >> 29054757

MiR-767 promoted cell proliferation in human melanoma by suppressing CYLD expression.

Kejin Zhang1, Ling Guo2.   

Abstract

MicroRNAs (miRNAs) have emerged as critical regulators for cancer development and progression of human melanoma. However, the potential molecular mechanism of miR-767 in human melanoma has not been intensively investigated. In this present study, we confirmed that miR-767 was frequently up-regulated in human melanoma tissues and cell lines. Ectopic expression of miR-767 promoted cell proliferation in human melanoma cell lines A375 and WM35, whereas miR-767-in reversed the function. Bioinformatics analysis revealed that cylindromatosis (CYLD) was hypothesized to be a possible target gene of miR-767, and this was confirmed by luciferase activity assay. Knockdown of CYLD counteracted the proliferation arrest by miR-767-in in melanoma cells A375 and WM35. In conclusion, our study indicated that miR-767 acted as a role of tumor promoter by targeting CYLD in human melanoma, and might serve as a prognostic or therapeutic target for human melanoma.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CYLD; Cell proliferation; Human melanoma; miR-767

Mesh:

Substances:

Year:  2017        PMID: 29054757     DOI: 10.1016/j.gene.2017.10.055

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  21 in total

1.  An integrated framework for the identification of potential miRNA-disease association based on novel negative samples extraction strategy.

Authors:  Chun-Chun Wang; Xing Chen; Jun Yin; Jia Qu
Journal:  RNA Biol       Date:  2019-01-28       Impact factor: 4.652

2.  Genome-wide cross-cancer analysis illustrates the critical role of bimodal miRNA in patient survival and drug responses to PI3K inhibitors.

Authors:  Laura Moody; Guanying Bianca Xu; Yuan-Xiang Pan; Hong Chen
Journal:  PLoS Comput Biol       Date:  2022-05-31       Impact factor: 4.779

3.  Ultrasound-targeted microbubble destruction-mediated miR-767 inhibition suppresses tumor progression of non-small cell lung cancer.

Authors:  Xiaohua Li; Min Xu; Wenyu Lv; Xingwang Yang
Journal:  Exp Ther Med       Date:  2020-03-12       Impact factor: 2.447

Review 4.  MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

5.  The Role of miRNA-132 against Apoptosis and Oxidative Stress in Heart Failure.

Authors:  Xuelei Liu; Zhou Tong; Keyan Chen; Xiaofang Hu; Hongxu Jin; Mingxiao Hou
Journal:  Biomed Res Int       Date:  2018-02-25       Impact factor: 3.411

6.  lncRNA-MEG3 Suppresses the Proliferation and Invasion of Melanoma by Regulating CYLD Expression Mediated by Sponging miR-499-5p.

Authors:  Jianwen Long; Xianming Pi
Journal:  Biomed Res Int       Date:  2018-04-02       Impact factor: 3.411

7.  MIR-520f Regulated Itch Expression and Promoted Cell Proliferation in Human Melanoma Cells.

Authors:  Ming-Xia Sun; Qun An; La-Mei Chen; Ling Guo
Journal:  Dose Response       Date:  2020-05-04       Impact factor: 2.658

8.  CircRNA circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p/MAPK4 pathway.

Authors:  Yashu Feng; Ling Zhang; Jieying Wu; Bijay Khadka; Zhigang Fang; Jiaming Gu; Baoqiang Tang; Ruozhi Xiao; Guangjin Pan; Jiajun Liu
Journal:  J Exp Clin Cancer Res       Date:  2019-02-06

9.  Prognostic significance of deregulated microRNAs in uveal melanomas.

Authors:  Luca Falzone; Giovanni L Romano; Rossella Salemi; Claudio Bucolo; Barbara Tomasello; Gabriella Lupo; Carmelina D Anfuso; Demetrios A Spandidos; Massimo Libra; Saverio Candido
Journal:  Mol Med Rep       Date:  2019-02-11       Impact factor: 2.952

10.  Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p.

Authors:  Haiyan Liu; Yan Wu; Shunye Wang; Jie Jiang; Chenlu Zhang; Yijing Jiang; Xingfeng Wang; Lewen Hong; Hongming Huang
Journal:  BMC Cancer       Date:  2019-10-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.